GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genor Biopharma Holdings Ltd (HKSE:06998) » Definitions » 10-Year ROIIC %

Genor Biopharma Holdings (HKSE:06998) 10-Year ROIIC % : 1,450.39% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Genor Biopharma Holdings 10-Year ROIIC %?

10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year. Genor Biopharma Holdings does not have enough data to calculate 10-Year ROIIC %.


Genor Biopharma Holdings 10-Year ROIIC % Historical Data

The historical data trend for Genor Biopharma Holdings's 10-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genor Biopharma Holdings 10-Year ROIIC % Chart

Genor Biopharma Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
10-Year ROIIC %
Get a 7-Day Free Trial - - - - -

Genor Biopharma Holdings Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
10-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Genor Biopharma Holdings's 10-Year ROIIC %

For the Biotechnology subindustry, Genor Biopharma Holdings's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genor Biopharma Holdings's 10-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genor Biopharma Holdings's 10-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Genor Biopharma Holdings's 10-Year ROIIC % falls into.


;
;

Genor Biopharma Holdings 10-Year ROIIC % Calculation

Genor Biopharma Holdings's 10-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

10-Year ROIIC %=10-Year Incremental Net Operating Profit After Taxes (NOPAT)**/10-Year Incremental Invested Capital**
=( -751.6127982 (Dec. 2023) - (Dec. 2013) )/( 261.884 (Dec. 2023) - (Dec. 2013) )
=/
=N/A%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Genor Biopharma Holdings  (HKSE:06998) 10-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Genor Biopharma Holdings 10-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Genor Biopharma Holdings's 10-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Genor Biopharma Holdings Business Description

Traded in Other Exchanges
Address
690 Bibo Road, Room 401-17, Building 6, Pudong New District, Shanghai, CHN, 201203
Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates include GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.
Executives
Forebright New Opportunities Fund, L.p. 2101 Beneficial owner
Forbright Global Limited 2201 Interest of corporation controlled by you
Fnof Gp Limited 2201 Interest of corporation controlled by you
Deg – Deutsche Investitions- Und Entwicklungsgesellschaft Mbh 2101 Beneficial owner
Hsg Growth V Holdco Q, Ltd. 2101 Beneficial owner
Hsg Holding Limited 2201 Interest of corporation controlled by you
Snp China Enterprises Limited 2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund Management I, L.p. 2201 Interest of corporation controlled by you
Shen Nan Peng 2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund I, L.p. 2101 Beneficial owner
Hongshan Capital Growth Fund V, L.p. 2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p. 2201 Interest of corporation controlled by you
Hongshan Capital Management I, L.p. 2201 Interest of corporation controlled by you
Hongshan Capital I, L.p. 2101 Beneficial owner
Ni Xin 2101 Beneficial owner

Genor Biopharma Holdings Headlines

No Headlines